Morpholino

MO2-slco2b1

ID

ZDB-MRPHLNO-221028-1

Name

MO2-slco2b1

Previous Names

None

Target

slco2b1 (1)

Sequence

5' - CATCCATGCTTTTTATCCTTGCCTC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

Splice-blocking MO.

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO2-slco2b1

No data available

Phenotype

Phenotype resulting from MO2-slco2b1

Phenotype	Fish	Figures
caudal hematopoietic tissue prostaglandin biosynthetic process decreased process quality, abnormal	bw9Tg/bw9Tg + MO2-slco2b1	Fig. 6 from Cacialli et al., 2022
caudal hematopoietic tissue regulation of prostaglandin-E synthase activity decreased process quality, abnormal	bw9Tg/bw9Tg + MO2-slco2b1	Fig. 6 from Cacialli et al., 2022
endothelial cell regulation of prostaglandin-E synthase activity decreased process quality, abnormal	bw9Tg/bw9Tg + MO2-slco2b1	Fig. 6 from Cacialli et al., 2022

Phenotype of all Fish created by or utilizing MO2-slco2b1

Phenotype	Fish	Conditions	Figures
caudal hematopoietic tissue prostaglandin biosynthetic process decreased process quality, abnormal	bw9Tg/bw9Tg + MO2-slco2b1	standard conditions	Fig. 6 from Cacialli et al., 2022
endothelial cell regulation of prostaglandin-E synthase activity decreased process quality, abnormal	bw9Tg/bw9Tg + MO2-slco2b1	standard conditions	Fig. 6 from Cacialli et al., 2022
caudal hematopoietic tissue regulation of prostaglandin-E synthase activity decreased process quality, abnormal	bw9Tg/bw9Tg + MO2-slco2b1	standard conditions	Fig. 6 from Cacialli et al., 2022
caudal hematopoietic tissue hematopoietic multipotent progenitor cell GFP expression decreased amount, abnormal	zf169Tg/zf169Tg + MO2-slco2b1	standard conditions	Fig. 4 from Cacialli et al., 2022
caudal hematopoietic tissue hematopoietic multipotent progenitor cell GFP expression amount, ameliorated	zf169Tg/zf169Tg + MO2-slco2b1	chemical treatment by environment: prostaglandin E2	Fig. 4 from Cacialli et al., 2022
regulation of prostaglandin-E synthase activity decreased process quality, abnormal	zf169Tg/zf169Tg + MO2-slco2b1	standard conditions	Fig. 4 from Cacialli et al., 2022
caudal hematopoietic tissue hematopoietic stem cell proliferation decreased frequency, abnormal	zf169Tg/zf169Tg + MO2-slco2b1	standard conditions	Fig. 4 from Cacialli et al., 2022
hematopoietic multipotent progenitor cell mCherry expression decreased amount, abnormal	cz2010Tg/cz2010Tg; ug108Tg/ug108Tg + MO2-slco2b1	chemical treatment by environment: metronidazole	Fig. 5 from Cacialli et al., 2022
hematopoietic multipotent progenitor cell mCherry expression decreased amount, abnormal	cz2010Tg/cz2010Tg; ug108Tg/ug108Tg + MO2-slco2b1	chemical treatment by environment: dimethyl sulfoxide	Fig. 5 from Cacialli et al., 2022
myeloid cell CFP expression decreased amount, abnormal	cz2010Tg/cz2010Tg; ug108Tg/ug108Tg + MO2-slco2b1	chemical treatment by environment: metronidazole	Fig. 5 from Cacialli et al., 2022
myeloid cell CFP expression decreased amount, abnormal	cz2010Tg/cz2010Tg; ug108Tg/ug108Tg + MO2-slco2b1	chemical treatment by environment: metronidazole, chemical treatment by environment: prostaglandin H2	Fig. 5 from Cacialli et al., 2022
hematopoietic multipotent progenitor cell mCherry expression decreased amount, abnormal	cz2010Tg/cz2010Tg; ug108Tg/ug108Tg + MO2-slco2b1	chemical treatment by environment: metronidazole, chemical treatment by environment: prostaglandin H2	Fig. 5 from Cacialli et al., 2022
blood vessel endothelium hematopoietic multipotent progenitor cell separated from blood vessel endothelium, abnormal	s896Tg/s896Tg; zf169Tg/zf169Tg + MO2-slco2b1	standard conditions	Fig. 3 from Cacialli et al., 2022
hematopoietic multipotent progenitor cell GFP expression decreased amount, abnormal	s896Tg/s896Tg; zf169Tg/zf169Tg + MO2-slco2b1	standard conditions	Fig. 3 from Cacialli et al., 2022

Citations